PROTOMED LIMITED

Company number 06328310 ·

Dissolved

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Market Position & Context

Protomed Limited operated in the UK's "other human health activities" segment (SIC 86900) — a broad category encompassing specialist, patient-facing health services outside core hospital and primary care. The defining feature of its market position is that it was never a standalone competitor: the register shows a corporate parent, Quantum Pharma Group Limited / Quantum Pharmaceutical Limited, holding more than 75% of shares and voting rights, with the right to appoint and remove directors. The registered office at the group's Gosforth headquarters confirms this was an integrated group entity rather than an independent operator.

The company has since been dissolved. Its last filed accounts were made up to 31 January 2017, and its final confirmation statement was filed in July 2018 — a pattern consistent with an orderly wind-down or absorption of activities elsewhere within the group well before strike-off.

Strategic Assets

  • Meaningful capitalization: Share capital of ~£378,695 is substantial for a private subsidiary. The non-round figure is characteristic of acquisition- or restructuring-related share issuance, suggesting the business entered the group as a going concern with real assets or intellectual property, rather than being built organically.
  • Parent-backed moat: Access to group regulatory infrastructure, manufacturing and distribution channels, and balance-sheet support — a significant advantage in a compliance-intensive sector where scale and quality systems are barriers to entry.
  • Defensive sector exposure: Human health services benefit from structural tailwinds — an ageing population, rising polypharmacy, and sustained NHS pressure to shift care into community and home settings.
  • Governance discipline: Filing full accounts rather than abbreviated formats reflects group-grade reporting standards, which supports counterparty and regulator confidence.

Growth Opportunities

The opportunity set that surrounded this asset — and remains relevant to any successor owner of similar capabilities — includes:

  • Medication adherence and monitored-dosage services: Demographics and chronic-care trends continue to expand demand for solutions that improve compliance and reduce hospital admissions.
  • Homecare channel expansion: The structural shift of care out of acute settings favours operators embedded in community pharmacy and homecare networks.
  • Group cross-selling: As a subsidiary, Protomed was positioned to leverage the parent's specials manufacturing and pharmacy distribution relationships — a route to scale that independent peers would lack.
  • Data-enabled services: Patient-level adherence data offers adjacency into higher-margin digital health and outcomes-based contracting.

Strategic Risks

  • Zero strategic autonomy: With >75% control and director appointment rights held by the parent, the company's fate was decided at group level. Its dissolution reads as portfolio rationalization — a common outcome when pharmaceutical services groups consolidate — rather than necessarily a verdict on the underlying market.
  • Value leakage on wind-down: The five-plus-year gap between the last accounts (2017) and dissolution suggests the entity ceased meaningful trading long before strike-off. Where assets or IP are transferred intra-group during such run-downs, minority-stake value can be diluted — though the available record does not show how assets were treated.
  • Disclosure opacity: No profit-and-loss or balance-sheet detail is available in the data beyond share capital, limiting external visibility of performance through its final decade.
  • Sector capital intensity: Regulatory approval cycles, quality-assurance overhead, and reimbursement dependence in UK healthcare reward scale; small subsidiaries are perennially vulnerable to consolidation decisions made above them.

Perspective: Strategic Business Consultant · Model: kimi-k3 · Generated 11 November 2026